Senzime AB Company Description

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States.

It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current.

The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system.

Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.

Senzime AB (publ)

Country	Sweden
Founded	1999
Industry	Medical Devices
Sector	Healthcare
Employees	52
CEO	Philip Siberg

Contact Details

Address: Ulls vAeg 41 Uppsala, 756 51 Sweden
Phone	46 18 51 56 40
Website	senzime.com

Stock Details

Ticker Symbol	SEZI
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0002478776
SIC Code	3845

Key Executives

Name	Position
Philip Siberg	Chief Executive Officer
Slavoljub Grujicic	Chief Financial Officer
Johanna Tulkki	Chief Operating Officer
Fredrik Norrby	Chief Technology Officer
Rianne Lundqvist Waninge Ph.D.	Application Scientist
Paula Treutiger	Head of Communication and Investor Relations
Anders Selin	Executive Vice President of Sales
Michael Noble	Vice President Global Marketing
Anders Jacobson	Chief Innovation Officer
Catrin Molund	Executive Vice President of Business Development